High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction DOI Creative Commons
Seong‐Uk Baek, Jin‐Ha Yoon

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1468 - 1468

Published: Nov. 18, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a recently introduced term for (SLD). Although the inflammatory process central to pathogenesis of SLD, research investigating differences in systemic inflammation across various SLD subtypes as well sex limited. This population-based, cross-sectional study investigated association between and high-sensitivity C-reactive protein (hs-CRP) levels among Korean adults (N = 20,141; mean age: 50.8 ± 16.7 years). The participants were classified into five groups that included no MASLD, metabolic alcohol-associated (MetALD), alcoholic with dysfunction (ALD MD), other SLDs. median (Q1, Q3) value hs-CRP level was 0.54 mg/L (0.33, 1.04). Among men, compared group, MetALD, ALD MD associated 41.9% (95% confidence interval [CI]: 35.1-49.1%), 46.8% CI: 35.0-59.6%), 51.8% 30.0-77.2%) increases levels, respectively. stronger women, 81.5% 73.6-89.8%), 84.3% 58.1-114.8%), 98.2% 38.0-184.8%) In conclusion, our findings indicate varying profile subtypes, more pronounced women

Language: Английский

Dapansutrile Regulates Mitochondrial Oxidative Stress and Reduces Hepatic Lipid Accumulation in Diabetic Mice DOI Creative Commons
Ying Wu, Jiaqiang Zhou

Current Issues in Molecular Biology, Journal Year: 2025, Volume and Issue: 47(3), P. 148 - 148

Published: Feb. 25, 2025

(1) Background: Hepatic lipid accumulation is the initial factor in metabolic-associated fatty liver disease (MAFLD) type 2 diabetics, leading to accelerated damage. The NOD-like receptor protein 3 (NLRP3) inflammasome plays a critical role this process. Dapansutrile (DAPA) novel NLRP3 inhibitor; however, its effect on ectopic remains unclear. This study aimed investigate therapeutic of DAPA hepatic diabetic mouse model and potential mechanisms. (2) Methods: effects deposition function under metabolic stress were evaluated vivo using db/db high-fat diet (HFD) + streptozotocin (STZ) models. Additionally, mechanism cellular deposition, mitochondrial oxidative stress, inflammation assessed HepG2 cells treated with free acids (FFA) DAPA. (3) Results: Our findings indicated that treatment improved glucose metabolism mice, particularly addressing heterotopic insulin resistance. also ameliorated mitochondrial-related functions through NLRP3-Caspase-1 signaling axis. (4) Conclusions: Targeting may represent approach for diabetes-related diseases.

Language: Английский

Citations

0
Epigallocatechin Gallate Alleviates Lipopolysaccharide-Induced Intestinal Inflammation in Wenchang Chicken by Inhibiting the TLR4/MyD88/NF-κB Signaling Pathway DOI Creative Commons
Xin Xu, Kunpeng Li, Qian Liu

et al.

Veterinary Sciences, Journal Year: 2025, Volume and Issue: 12(3), P. 225 - 225

Published: March 2, 2025

Intestinal inflammation significantly compromises broiler health and adversely affects growth performance. Epigallocatechin gallate (EGCG) was found to maintain the gut of animals. However, role mechanism EGCG in preventing lipopolysaccharide (LPS)-induced intestinal chicks have not yet been fully elucidated. In 35-day study, 140 one-day-old Wenchang chickens were randomly assigned four treatments: CON (basal diet), LPS diet + 1 mg/kg body weight (BW) LPS), L-EGCG 40 BW H-EGCG 60 LPS). On days 31, 33, 35 age, broilers LPS, L-EGCG, treatments received intraperitoneal injections LPS. The reduced jejunal villus height, height/crypt depth ratio, Claudin1 mRNA, catalase (CAT) activity, interleukin-10 (IL-10) levels compared while elevating diamine oxidase (DAO), interleukin-1β (IL-1β), tumor necrosis factor α (TNF-α). improved performance LPS-challenged broilers, height Claudin1/ZO-1 mRNA with serum DAO. It enhanced antioxidant capacity via increased total (T-AOC), superoxide dismutase (T-SOD), CAT, glutathione peroxidase (GSH-Px) activities, a decreased malondialdehyde (MDA) concentration. Concurrently, lowered IL-1β/TNF-α raised IL-10 serum/jejunum. Crucially, suppressed TLR4/MyD88/NF-κB protein expression under These findings demonstrate EGCG’s protective against LPS-induced through pathway inhibition.

Language: Английский

Citations

0
Gut microbiota in patients with metabolic, dysfunction-associated steatotic liver disease DOI

Lissette Duarte,

Fabien Magne,

Martín Gotteland

et al.

Current Opinion in Clinical Nutrition & Metabolic Care, Journal Year: 2025, Volume and Issue: unknown

Published: April 24, 2025

Purpose of review Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition that can progress to fibrosis, steatohepatitis, and hepatocellular carcinoma. This examines recent advances concerning the role gut microbiota in MASLD microbiota-focused interventions positively impact outcome. Recent findings Dysbiotic compromised barrier facilitate translocation microbial-associated molecular patterns harmful metabolites into portal circulation liver, where they exacerbate inflammatory fibrogenic processes. Conversely, other bacterial have protective effects liver. Therefore, homeostasis essential for maintaining health. Summary Levels including ethanol, NH 3 , trimethylamine-L-oxide, 2-oleylglycerol, litocholic acid are often increased patients with MASLD. short-chain fatty acids, indole derivatives, histidine, acids taurodeoxycholic, 3-succinylcholic, hyodeoxycholic decreased. The main aim current interventions/treatments reduce increase beneficial ones. These include drugs (pemafibrate, metformin, obeticholic acid), natural compounds (silymarin, lupeol, dietary fiber, peptides), exogenous bacteria (probiotics, symbionts), special diets (Mediterranean diet, time-restricted feeding), as well transplantation, phage therapy. Most improve permeability, inflammation, fibrosis through regulation, promising alternatives MASLFD management. However, most results come from animal studies, while clinical trials lacking. Further research therefore needed this area.

Language: Английский

Citations

0
Metabolic Dysfunction-Associated Steatotic Liver Disease: The Associations Between Inflammatory Markers, TLR4, and Cytokines IL-17A/F, and their Connections to the Degree of Steatosis and the Risk of Fibrosis DOI Creative Commons
Sorina Cezara Coste, Olga Hilda Orășan, Angela Cozma

et al.

Biomedicines, Journal Year: 2024, Volume and Issue: 12(9), P. 2144 - 2144

Published: Sept. 21, 2024

: The pathogenesis of MASLD (metabolic dysfunction-associated steatotic liver disease) is driven by environmental, genetic, metabolic, immune, and inflammatory factors. IL-17 TLR4 determine hepatic steatosis, inflammation, finally fibrosis.

Language: Английский

Citations

3
High-Sensitivity C-Reactive Protein Levels in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), Metabolic Alcohol-Associated Liver Disease (MetALD), and Alcoholic Liver Disease (ALD) with Metabolic Dysfunction DOI Creative Commons
Seong‐Uk Baek, Jin‐Ha Yoon

Biomolecules, Journal Year: 2024, Volume and Issue: 14(11), P. 1468 - 1468

Published: Nov. 18, 2024

Metabolic dysfunction-associated steatotic liver disease (MASLD) is a recently introduced term for (SLD). Although the inflammatory process central to pathogenesis of SLD, research investigating differences in systemic inflammation across various SLD subtypes as well sex limited. This population-based, cross-sectional study investigated association between and high-sensitivity C-reactive protein (hs-CRP) levels among Korean adults (N = 20,141; mean age: 50.8 ± 16.7 years). The participants were classified into five groups that included no MASLD, metabolic alcohol-associated (MetALD), alcoholic with dysfunction (ALD MD), other SLDs. median (Q1, Q3) value hs-CRP level was 0.54 mg/L (0.33, 1.04). Among men, compared group, MetALD, ALD MD associated 41.9% (95% confidence interval [CI]: 35.1-49.1%), 46.8% CI: 35.0-59.6%), 51.8% 30.0-77.2%) increases levels, respectively. stronger women, 81.5% 73.6-89.8%), 84.3% 58.1-114.8%), 98.2% 38.0-184.8%) In conclusion, our findings indicate varying profile subtypes, more pronounced women

Language: Английский

Citations

1